• HUGE : NASDAQ • HUGE : CSE • OK9A : FRA
PROCESSING & MANUFACTURING
PHARMA RESEARCH & DEVELOPMENT
FSD’s R&D platform focuses on synthetic compounds that target the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. With the acquisition of Prismic Pharmaceuticals, FSD is also making an effort to help address the opioid crisis by developing opioid-sparing prescription drugs utilizing the micronized formulations of palmitolyethanolamide (PEA).
No long term debt
Generated $7.7M proceeds and 670% return on investment through monetizing equity stake in Cannara Biotech
Non-cash assets over $72 M
Copyright © 2020. All rights reserved.